AMN Healthcare Services, Inc. (NYSE:AMN) Q4 2022 Earnings Call Transcript

AMN Healthcare Services, Inc. (NYSE:AMN) Q4 2022 Earnings Call Transcript February 16, 2023

Operator: Good day, and welcome to AMN Healthcare Fourth Quarter 2022 Earnings Call. At this all participants are in a listen-only mode. After the speaker presentation there will be a question and answer session. . Please be advice that today’s conference is being recording. I would now like to hand the call over to your speaker Mr. Randle Reece, Senior Director of Investor Relations. Please go ahead sir.

Randle Reece: Good afternoon, everyone. Welcome to AMN Healthcare’s fourth quarter and full year 2022 earnings call. A replay of this webcast will be available at ir.amnhealthcare.com following the conclusion of this call. Various remarks we make during this call about future expectations, projections, trends, plans, events or circumstances constitute forward-looking statements. These statements reflect the company’s current beliefs based upon information currently available to it. Our actual results may differ materially from those indicated by these forward-looking statements, because of various factors and cautionary statements, including those identified in our most recently filed forms 10-K and 10-Q, our earnings release and subsequent filings with the SEC.

The company does not intend to update guidance or any forward-looking statements provided today prior to its next earnings release. This call contains certain non-GAAP financial information. Information regarding and reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are included in our earnings release and on our financial reports page at ir.amnhealthcare.com. On the call today are Cary Grace. Chief Executive Officer, Jeff Knudson, Chief Financial Officer; Kelly Rakowski, Group President and COO of Strategic Talent Solutions; and Landry Seedig, Group President and COO of Nursing and Allied Solutions. James Taylor, President and Chief Operating Officer of Physician and Leadership Solutions, in unavailable today.

I will now turn the call over to Cary.

Cary Grace: Thank you, Randle, and welcome everyone. I want to begin by expressing my gratitude for the warm welcome I have received by the AMN team, our board of directors, investors and analysts and our clients since my time as CEO began in late November. The past few months have more than confirmed all the reasons why I joined AMN. AMN stands at the nexus of healthcare and talent, where we make an increasingly valuable difference in the quality and timeliness of care. My experience running large client centered service delivery businesses that combine organic growth and acquisitions positions me well to help guide AMN through its next phase of growth. And though everybody says they have a great company culture, AMN truly has something special.

Our entire leadership team is committed to live in the AMN difference every day, and making sure we create great long-term opportunities for everyone in our organization. I’m especially grateful to report good news in my first AMN conference call with outstanding fourth quarter results, and a strong first quarter outlook. Thank you to our healthcare professionals and team members for making a valuable impact for our clients in 2022, with more than 250,000 placements as our country managed through the pandemic. I am proud of how we are partnering with clients to optimize their labor costs, reducing bill rates as the urgency of demand moderated and investing in tech-enabled solutions to help our clients transform care delivery models and manage their workforces over the long-term.

We remain the preferred partner for healthcare clients with our MSP and BMS programs managing more than $12 billion of labor spent in 2022. AMN is a preferred employer for healthcare professionals and corporate team members, as demonstrated by several recent accolades we received, including the Diversity Equity and Inclusion award from the National Association of Corporate Directors and being named to the Bloomberg Gender Equality Index for our commitment to gender equality and equity for a sixth year in a row. Over the past year, as we managed through extremely high demand, we were looking ahead, anticipating a moderation with the wind down of the pandemic, our businesses exceeded the expectations we laid out a year ago. Our high level of performance is apparent in our latest financial results and outlook for the current quarter.

Fourth quarter revenue was $1.13 billion with adjusted EBITDA of $175 million. Every business segment exceeded guidance and what continues to be a fast changing market. Nurse and Allied segment revenue was ahead of expectation since the fourth quarter, nearly flat with the third quarter despite lower labor disruption revenue. The moderation of bill rates was somewhat less than we had anticipated, with a segment average bill rate coming in 23% lower than the first quarter peak. As expected volume in travel nurse was higher than the third quarter offset by the lower average bill rate. Demand for travel nursing remains above 2019 levels, even after the healthcare sector maintained an impressive pace of permanent hiring over the past eight months.

Our Allied business has 6% year-over-year revenue growth with a 3% sequential increase. The team did a phenomenal job pivoting focus from pandemic related specialties, to therapy and other areas. For the first quarter of 2023, we expect revenue in Nurse and Allied Solutions to be stable sequentially, and down 32% to 34% year-over-year against our most difficult comparison of the year. In our Physician and Leadership Solution segment, fourth quarter revenue was slightly better than our guidance. Locum tenens is operating at a consistently high level with four consecutive quarters over $100 million of revenue. Interim Leadership and Search achieved record high revenue for the year. As we expected, demand for Interim Leadership and Search was lower in the fourth quarter at some clients focus on short term cost savings.

In the first quarter, we projected revenue and Physician and Leadership Solutions to be down 10% to 12% year-over-year, excluding pandemic related business revenue would be flat to prior year. Demand is well above pre-pandemic levels for locum tenens and physician permanent placement. In Technology and Workforce Solutions revenue grew 14% year-over-year, better than our guidance of about 10% growth. Our Language Services business was the primary driver of the outperformance Since AMN acquired the company in 2020, Language Services has doubled its revenue, a great example of how we can add value with acquisition. It is further evidence of our commitment to innovation, supporting quality patient care, and making a positive impact to the communities we serve.

In 2022 alone, we enhance the health care experience outcomes for patients in over 15 million interactions. Also in this segment, VMS revenue continued its moderation in line with our expectations. For the first quarter, we expect revenue and Technology and Workforce Solutions to be down 10% to 12% year-over-year due to lower VMS revenue. Now, I’ll turn over the call to Jeff for more details about our results and outlook, after which I will return to provide a glimpse at our focus areas for 2023 and beyond.

Jeff Knudson: Thank you, Cary, and good afternoon everyone. Fourth quarter revenue of $1.126 billion was 4% above the high end of our guidance range with all three segments contributing to the outperformance. Consolidated revenue was down 17% year-over-year and 1% sequentially, excluding labor disruption revenue, consolidated revenue was in line with the prior quarter. Gross margin for the quarter was 33.3%, 140 basis points higher than prior year and down 50 basis points sequentially. Year-over-year, the margin was hired due to a revenue mix shift toward higher margin businesses. Sequentially, the margin was lower due to the typical seasonal revenue mix shift towards staffing. Consolidated SG&A expenses were $219 million or 19.5% of revenue, compared with $239 million or 17.5% of revenue in the year ago quarter, and $215 million or 18.9% of revenue in the previous quarter.

Surgery, Medicine, Health

Photo by Hush Naidoo Jade on Unsplash

SG&A expenses were lower year-over-year primarily due to lower employee related expenses, given less revenue and more normal operating conditions. Higher allowances for credit losses and legal reserve expenses drove the increase in SG&A compared with the prior quarter. Adjusted SG&A. excluding certain non-recurring expenses and stock-based compensation expense was $202 million this quarter, or 17.9% of revenue compared with $212 million or 15.6% of revenue in the year ago quarter. The increase in adjusted SG&A margin came from less operating leverage on lower revenue. In the fourth quarter, Nurse and Allied revenue was $825 million, 24% lower than prior year and slightly down sequentially. Average bill rate was lower by 2% quarter-over-quarter and average hours down 1%, offsetting 3% higher volume.

Our travel nurse revenue was down 24% versus prior year and flat sequentially. Allied revenue was $195 million growing 6% from the prior year and 3% above prior quarter. Nurse and Allied gross margin of 26.6% was 40 basis points lower than prior year and prior quarter. The year-over-year change was caused by less labor disruption revenue, lower average hours and higher insurance expenses partially offset by improvement in the bill pay spread. Sequentially, the margin decreased stem primarily from the favorable workers compensation adjustments that occurred in Q3, segment operating margin of 12.7% was 370 basis points lower than prior year and 120 basis points lower than prior quarter, reflecting the higher allowances for credit losses. Physician and Leadership Solutions revenue in the fourth quarter was $168 million, 2% higher year-over-year and down 4% sequentially.

Locum tenens revenue was $103 million, 4% higher than prior year or growing by 13%, excluding pandemic related revenue. Interim leadership revenue increased 4% from prior year and was down 5% from prior quarter. Search revenue declined 10% from prior year and was down 13% sequentially. Gross margin for this segment was 35%, 100 basis points higher than prior quarter and down 10 basis points year over year. The sequential margin increase was primarily due to higher gross margin for locum tenens partially offset by mix. Segment operating margin was 16.7%, up 510 basis points from last year and up 310 basis points sequentially. The higher profit margin came primarily from a lower allowance for credit losses and a favorable actuarial adjustment.

Technology and Workforce Solutions revenue was $133 million in the fourth quarter, growing 14% year-over-year and down 1% sequentially. Language Services stood out with revenue of $58 million, which grew 23% year-over-year, and 5% quarter-over-quarter, BMS revenue of $55 million grew 5% year-over-year and was down 9% from prior quarter as we had expected. Segment gross margin was 73.3%, up 130 basis points over prior year and down 230 basis points sequentially. The year-over-year and sequential changes track revenue comparisons for the higher margin BMS business. Segment operating margin of 50.2% was up 280 basis points year-over-year and down 250 basis points sequentially. Consolidated fourth quarter adjusted EBITDA of $175 million was lower by 22% year-over-year and down 4% from the prior quarter.

Adjusted EBITDA margin of 15.5% was 80 basis points lower year-over-year and down 50 basis points sequentially. We reported net income of $82 million and diluted earnings per share of $1.88 in the quarter. Adjusted earnings per share was $2.48 compared with $2.95 in the year ago quarter. Day sales outstanding came in better than expected at 55 days, four days less than the prior quarter and two days higher than prior year. Operating cash flow for the quarter was $115 million and capital expenditures were $25 million. As of December 31st, we had cash equivalents of $65 million, long-term debt of $850 million and a net leverage ratio of one time to one Recapping financial highlights for the full year 2022, we reported revenue of $5.2 4 billion, a 32% year-over-year increase and net income of $444 million, which grew by 36% compared with 2021.

Adjusted EBITDA was $847 million, up 33% from prior year. Full year adjusted EBITDA margin of 16.1% was 20 basis points higher year-over-year. GAAP EPS was $9.90, up 45% year-over-year, adjusted EPS was $11.90 higher than prior year by 48%. EPS benefited from our repurchases of $577 million in stock during the year. Full year cash flow from operations was $654 million, which included a $24 million payment of deferred payroll taxes from the Cares Act, adjusting for the Cares Act repayment. nearly 80% of our adjusted EBITDA was converted into cash flow from operations. Capital expenditures totaled 76 million. Since the end of 2022, two events have bolstered our capital strategy, we obtained an expansion of our revolving line of credit adding $350 million of borrowing capacity to total $750 million with its tenor extended to 2028.

The interest rate for the expanded facility is in line with previous terms. In addition, the Board of Directors expanded our share repurchase authorization by $500 million. Since our last earnings call, we bought back 2.4 million shares of stock for $275 million. The latest authorization gives us a total of $551 million in potential buybacks. Now looking at first quarter 2023 guidance. We project consolidated revenue to be in a range of $1.1 billion to $1.13 billion, down 27% to 29% over prior year. Gross margin is projected to be 32.6% to 33.1%. Reported SG&A expenses are projected to be 18.3% to 18.8% of revenue. Operating margin is expected to be 11% to 11.7%, and adjusted EBITDA margin is expected to be 15.4% to 15.9%. Average diluted shares outstanding are projected to be $42 million, reflecting our recent share repurchase activity.

Other first quarter guidance details can be found in today’s earnings release. Last quarter, we talked about 2023 returning to a normal seasonal pattern. Our fourth quarter results and first quarter outlook came in stronger than we had expected, with higher bill rates being a key driver. After the Q1 strength current business trends suggest a decline in Nurse and Allied revenue for Q2 that is greater than normal seasonality. While demand is still above pre pandemic levels, we have seen some clients pursue near term cost savings and reduce utilization of contingent staff. Labor market conditions remain very tight with high vacancies and attrition. And we believe staffing demand will go back up over the summer in line with normal seasonality.

And now, I’d like to hand the call back to Cary.

Cary Grace: Thank you, Jeff. While the healthcare sector hired more than 9 million people in 2022, that hiring spree resulted in a net employment increase of less than 800,000. Competition for talent remains intense, and wage inflation is elevated. Voluntary turnover remains at the highest level in more than 20 years, and conditions are most difficult for our clients in acute care. Recognizing these enduring issues, we are focused on four key areas that we believe will drive long-term value for all our stakeholders. First, we will continue to be the preferred partner for health care organizations, as they optimize their workforce strategy to meet continued long-term increases in utilization. Our solutions that is comprehensive and differentiated and will be more so with our internal investments and acquisition strategy.

We see great opportunity both in better serving current clients and winning new clients. On that path, we will strengthen our ability to go-to-market as one AMN building brand equity and making it easier for clients and healthcare professionals to work with us. We are already gaining traction on initiatives to improve our speed to deliver while maintaining our industry leading quality. As demand has receded from its extreme highs, our MSP strategy better positions us to gain share. Second, we are standing our efforts to ensure AMN is the preferred employer for healthcare professionals and team members. These programs include new initiatives on workplace flexibility, ensuring competitive pay and benefits at all levels, career pathing and mentoring and industry leadership in diversity, equality, equity and inclusion.

Our health care professionals benefit from having the largest selection of job opportunities in the industry, easily accessed through mobile technology. Third, we want to keep building our diversified portfolio that is expanding and improving total talent solutions for healthcare. Our strategies to aggressively increase technology enablement in every aspect of AMN. Our plan will allocate approximately 2% of revenue to capital expenditures with a heavy focus on digital innovation. These investments will improve outcomes for our existing solutions, and add new technology led solutions to keep up with the challenge of delivering care amidst a sustained mismatch of supply and demand. We are continuing to invest in Digital First initiatives such as AMN Passport, are always on connection with more than 170,000 nurses and growing.

And finally, we are committed to being good stewards of capital. Our capital expenditures more than doubled over the past three years, enabling us to lead our industry and technology improvements. We have built a company with high quality of earnings and strong free cash flows that give us strategic options. With a strong balance sheet and expanded borrowing capacity, we have the framework and flexibility to make attractive acquisitions, while also repurchasing stock, which we believe is a great investment opportunity. Now, let’s please open the call for questions.

See also 12 Countries that Export the Most Textiles and 12 Countries that Export the Most Tea.

Q&A Session

Follow Ameron International Corp (NYSE:AMN)

Operator: Thank you. And our first question will come from the line of Kevin Fischbeck with Bank of America. Please go ahead.

Kevin Fischbeck: Great. Thanks. I guess, you’re basically flat earnings sequentially, and Q1 speak to some stability there. But there’s always seasonality in that from Q4 to Q1. And I think the big debate right now, it’s just kind of, where the new normal is in your view around healthcare staffing demand? I was really helpful to hear your comments about the seasonal drop into Q2, but as your view on Q2 change? Is it more about Q1 being higher than it is about Q2 being lower? And I guess, we should be here kind of again, Q2 change from where you were when you were giving guidance last time?

Cary Grace: Hi, Kevin, thanks for the questions. Maybe what we’ll do is, I’ll turn it over to Jeff, who’ll talk a little bit about the patterning of Q1, Q2, and then Landry and I can talk a little bit more broadly about demand.

Jeff Knudson: Yes, Kevin. So, the first quarter guidance is higher than what we would have originally thought really primarily driven from higher bill rates, and that’s partially driven by a mix with some higher rate orders that we’ll be rolling off at the end of Q1. So, as a result, we are expecting a higher than normal sequential decline in Nurse and Allied revenue from Q1 to Q2. And if we just step back and think about Q2 going into the year, we would have expected the second quarter to be the lowest revenue and EBITDA margin quarter of the year, and that is still the case. On the Nurse and Allied side, we would normally expect a 6% sequential decline in the second quarter, looking at historical patterns and that’s normalized for labor disruption driven by the winner orders winding down and that 6% would be driven by equal declines in both volume and bill rates.

So, as the bill rates were higher in both the fourth and the first quarter, we do now expect a high single digit bill rate decline in the second quarter, again, primarily driven by that mix influence from Q1 and the normal seasonality. And then, we would expect the second quarter sequential volume decline to be higher than our historical seasonality, but less than the bill rate declines.

Cary Grace: Hey, Kevin, if we kind of step back and take the demand question, let me kind of give you a perspective on what we see is the shape of demand and some of the factors around supply that we’re seeing. And then, I’ll have Landry comment a little bit more on what we’ve been seeing more recently. So, if I go back into the onset of the pandemic, it really accelerated an existing supply/demand imbalance across the healthcare workforce. And as we’ve moderated down from the emergency demand levels, we saw during the pandemic, we still have an enduring structural change in the supply of and demand for these health care professionals. So the things that we are seeing and continuing to track is you’re seeing continued utilization demand growing, so I think people are pegging it somewhere kind of five plus percent annually.

The new supply, especially of nurses is not keeping up with these increases, and the already constrained supply of the healthcare professionals is being impacted by retirement. So, the same demographics that are driving some of the increases in demand, are also driving the accelerated retirement of some of our health care professionals. And we also continue to see bedside clinicians leaving and taking less stressful jobs in health care and elsewhere. Beyond these supply/demand enduring imbalances, we’re seeing compensation expectations that have increased across all economic sectors, as high inflation has put upward pressure on wages. And so that really was happening throughout the pandemic. So, the conversations we’ve been talking to our clients about is, how do we help them attract and retain the workforce they need to serve their patients in a cost effective way.

So, enduring structural supply demand imbalance, continued upward, kind of leaving point from the pandemic of pressure on wages. And I’ll turn it over to Landry to talk a little bit about what we’re seeing more recently.

Landry Seedig: Yes. Hi, Kevin. So, we do as of today, we continue to see travel nurse and allied demand that is above pre-pandemic levels. It is down from some of the highs that we saw in the industry during some of those major COVID spikes. But you really have to think about at the peak, a lot of that demand as what we would kind of characterize as irrelevant, and it never did get filled by the overall industry. So you had demand spiking because of the extreme needs that exist there and the inadequate labor supply that exists. We’ve been predicting all along that we wouldn’t have as high of demand whenever things settle down. Yet, that demand still would be higher than pre pandemic levels, just to some of those — due to some of those universal issues on the labor within healthcare.

We have seen a couple of reports out there on demand in the marketplace that reflect what others might be seeing in the industry. And while our demand is down, as I just mentioned, our decline has not been as steep as what some of those reports suggest. I think there’s a couple of reasons for that. I think one reason is that we stay true to our MSP customers over the past few years. And also the AMN team really did not chase any of the kind of what we would consider short-term business over the past couple of years. Lot of our conversations right now with clients are about reducing cost. But the reality is that their facilities remain highly understaffed even today. Bill rates, they’ve moderated for the most part, so clients are looking for decreases in their order volume really to try to accomplish a lot of their contingent labor expense targets.

And then, if you look at some of the underlying drivers of supply and demand, we expect that the pullback is going to be pretty short-term, and it’s really just overall not sustainable in the marketplace. So, we do expect to see a healthy demand environment as we progress throughout the year. There’s quite a bit of levers that we’re pulling right now, things like increasing our MSP fill rates, and then also returning our internal capture to some historical levels. We saw that dip a little bit throughout the pandemic whenever demand was really high and we were highly reliant on our supplier partners. And then the last think that that I’d mentioned is that we also have opportunities to focus in more on our non-MSPs, which we had previously been over the past couple of years.

Kevin Fischbeck: Okay. That’s fantastic. And I just do one more. I guess, Cary, whenever there’s a new CEO, always looking to see kind of what they’re focusing more on now. And I guess in your prepared comments, this go as one AMN thing kind of stuck out to me. Any way to size kind of what you see the opportunity as and how we should think about what that could mean? Thanks.

Cary Grace: Yes. Let me — thanks, Kevin. Let me give you a little bit of perspective at a macro level. And as we continue on these calls throughout the year, I’ll continue to put color on it. So one AMN, I know there’s going to be a very physical representation of that, where you will start to see our brands come together. So we will literally look more cohesive and integrated as one company. But really, a lot of the things that we are working incredibly hard on and will continue to throughout the year is how do we actually make all the parts across AMN work more seamlessly together. So there’s a lot of implications for work that we’re doing to streamline our processes across our 20 solution set to streamline our platform. And so a lot of what we want AMN to feel like is to feel easier to do business with, both for all of our clients, for our clinicians, and very importantly for our own team members.

If I gave you an example of what I would expect it to start changing in terms of the shape of our financials, as a proxy right now, if you look at our 30 largest clients, of our 20 solution, we have an average of eight. And so obviously, if you went much, much further across our client base and then kind of did the math around our 20 solutions, there’s tremendous opportunity for us to further penetrate those client relationships. And we’ll have more success in doing that and we’ve created a real and meaningful value proposition that’s compelling to them.

Kevin Fischbeck: Thanks.

Operator: Thank you. One moment for our next question, that will come from the line of A.J. Rice with Credit Suisse. Your line is open.

A.J. Rice : Hi, everybody. And congratulations, Cary on your first quarter here. Let me just maybe drill down a little bit further on some of the stuff that Landry was saying. So if you look at your MSP accounts, I know in the peak, you were having to — you couldn’t fill all the orders, the entire industry couldn’t fill all the orders, but you were subcontracting out a meaningful percentage. If you look at say, Q3 to Q4, are you stepping up the percentage that you’re filling of those open orders meaningfully? Or is it still a fair number that are being subcontracted and potentially even going among your MSP accounts?

Cary Grace: A.J., I was going to say, thank you for that. You got our strategy what we were doing throughout the pandemic, and also around what we have been doing subsequently. I’ll let Landry kind of kick off and then Kelly can talk a little bit about our broader MSP strategy.

Landry Seedig : Yes. So I’m going to turn that to Kelly, but I was just going to mention, A.J., both Q3 and Q4 are strong. So we were living in really high demand in the fourth quarter. And so those — you have to look at that as being pretty flat. And then right now our focus is on increasing that as we progress through Q1 and then going into Q2. And we are seeing increases on that, but I’ll let Kelly provide a little bit more detail.

Kelly Rakowski : Yes. A.J., just to build on that, certainly favorable trend for us as those demand — that demand lower from Q4 to Q1. We’re seeing both increased fulfillment as well as some increases — incremental increases in our internal capture. We will remain — our model will remain a combination of AMN’s ability to fulfill on behalf of our clients, but also the strength of our supplier network, which is critical for us to achieve that fulfillment as well as augment our capabilities in regional or specialized areas and we were very fortunate to have the strength of our suppliers throughout COVID as were our clients. So that strategy won’t change, although, we do have opportunities to grow that. And it also creates additional capacity for us, as we’re seeing pretty strong demand from a new business and pipeline perspective, A.J. So we’ve been very active in the market.

We added a few new MSPs in the last couple of quarters and a healthy pipeline for us here starting the year. So we will continue to grow our client base. And again, the strength of our network will be a key part of that growth.

A.J. Rice : Okay. And then just a follow-up. Is another comment you guys were making. So when you think about what happened in the pandemic, you had some new competitors come in and grab some marginal share. And there was always — like you said, you had to emphasize your MSP accounts and some of the other ones probably got less focus. As you’re thinking about having the opportunity to go back after some of that business, how sticky is it with the new competitors? Are people — are you finding that people are willing to come back to you pretty easily. And I wondered also whether it might create some opportunities on the M&A side. I know traditionally, a lot of your M&A has been adjacent businesses, but I wondered if there were opportunities emerging in the core Travel Nursing, Allied and Locums business you might look at.

Landry Seedig : So A.J., this is Landry. I can start with it. So we cover the non-MSP business, we never left it. We just deprioritized it and we still — nothing changed in our relationships. We were very transparent with whether those are direct contracts or where we are a third-party to some of those maybe other MSP or VMS holders out in the marketplace. So there was nothing that was being hidden. We were trying to find other solutions to try to help even some of those different types of clients out, whether that was through our VMS system or our local business or some other businesses. So, all those contracts still exist. We still get those orders. We can just prioritize them higher within our order rating numbers. Some of the short-term business that I was referring to that was just more of that kind of state contracts or some of the facilities that we’re setting up for vaccine centers, or stand up hospitals, or FEMA, some of those other programs that we thought would go away at some point and they, in fact, have.

So I think our strategy is staying highly focused on our MSP customers has been new retention rate of our MSP customers in the long run has had and will continue to play out well for us.

Cary Grace: And — okay

Kelly Rakowski : A.J., just to your last comment around as I reflect on some of the new business and new strategic relationships we’re bringing in, we are seeing some early traction as we go-to-market with a more comprehensive solution set and really emphasizing that and clients looking for more solutions as they faced a challenging market. So we have seen as one early indicator, the number of service lines per contract is going up with our new business versus in the past, where we started with contracts and saw growth over time. So we’ll expect to see that trend continue as well.

Cary Grace: Hey, A.J., on the M&A side, we expect M&A to continue to be an important part of our growth strategy. And so you should expect us to have a proactive focus on M&A, especially as ways that we think it can help us serve our clients more effectively. We will look at strategic fit, we’ll look at financial fit, we look at cultural fit, quality of management. We will look at more traditional staffing assets. We also will look at and have a focus on tech-enabled solutions. What I would say from kind of what we have seen standpoint, last year, we probably on bias saw more traditional staffing assets. I know it’s relatively early in the year, but we’re seeing relatively more tech-enabled solutions come up. And so know that we will look broadly, we will look and we are very interested in M&A as a growth strategy.

A.J. Rice : Okay. Great. Thanks a lot.

Operator: Thank you. One moment for our next question, that will come from the line of Tobey Sommer with Truist. Your line is open.

Tobey Sommer: Thank you. I wanted to see if you could spend some time giving us some more color on VMS and MSP trends. In particular, if you could touch on the — what seems like rapid adoption of vendor-neutral MSPs and VMS solutions and maybe also speak to any timing of recompetes for your larger MSPs? Thank you.

Cary Grace: Hey, Tobey. I’m going to turn it over to Kelly in a second, but as a frame up for this conversation, we have very intentionally built a broad set of capabilities. We know that clients have different needs; and they have different strategies for how they want to manage their workforce recruiting, retention staffing strategies. And so think of this as Kelly talks about some of those trends that we really do look at it and we start with the client need and then we work around from that and how we can be helpful to them and how they want to execute that strategy. So, Kelly, I’ll turn it over to you to talk about some of those trends.

Kelly Rakowski : Yes. Hi, Tobey, I would say, I’m not sure we’re seeing some of those trends. I will say, it’s pretty typical and we typically see on any given year from our own mix of business. Now it changed a little bit during COVID. But look at our pipeline over the last two years, in 2021, we saw heavier mix of technology-only solution. Now we start to see that come back. So I would say our pipeline today is more heavily weighted towards full MSP programs. And also, we see in our — because we have multiple VMS solutions and such a large client base, nearly 500, typically, in any given year, we’ll see some transition from clients who want to take their business in-house, and conversely those who want to transition from an in-house solution into our MSP program.

So we’ve had both of those play out in our client base. And again, I would say that is pretty typical to what we’ve seen in the past. So we are seeing, of course, clients want to add to their ability to have more flexible type solutions inside their workforce, I would say, it’s more of an to use of Travel Nurse. So things like internal flow pool. You did see some internal agency activity where they’re using VMS solutions to help accommodate that. And certainly, we are partnering with them in highly customized ways to meet their local needs. On the second part of your question, Tobey, around our outlook for our renewals and contracts. Again, we had a very strong retention rate last year. We have a very typical renewal period, as we look at our contracts coming to terms.

We have a very strong outlook this year for renewals. In fact, we’ve got several already in verbal. It’s not contracted this year. So, nothing is accelerating that or really changing that and a lot of the catch-up that it happened for laser and COVID have played out contracting over the past year.

Tobey Sommer: Thanks. For my follow-up, I wanted to see if I could get you to talk about why you think demand rebounds in the summer and for Travel Nurse. And if that’s nearly a reflection of reliance on history, a product of conversations and what customers are telling you, sort of how do you get that as a conclusion?

Cary Grace: No, I think, it really goes back to a combination of some of the comments that Jeff and Landry are making. So if you look at it from a macro standpoint and just look at the structural imbalance in supply and demand against the backdrop of — and there’s a — we just published some research on this just on timing and continued delays in access. We know that the demand continues to get pent up. And as much as clients right now are extremely focused on cost containment, they also are very focused on how are they going to staff to meet their demand. So, it’s a combination of what we’re seeing structurally. And second, that we have seen seasonal patterns typically where you start to get winter orders as you go through the summer. So, it’s really a combination of both of those things.

Landry Seedig : Yes, Tobey, I would just add. It’s just — it really is not sustainable. All of the lower demand is purely a CFO decision right now. We’re not seeing it from CMOs, we’re not seeing it from unit managers. It’s purely a financial decision. They are still understaffed. Nothing has changed there. And the reality is that, our Q1 volumes are good, it’s just the demand has been pulled back. That’s the solution that they’re thinking for cost savings, they haven’t felt the pain, right. So our clinicians are still there right now. And so whenever those clinicians start coming off, it will get noisy, their internal staff will be getting noisy, that we’ll experience even higher turnover. And it’s not — we saw it throughout the pandemic, but we’ve also seen this over the last 15 years. It’s just not sustainable whenever there is a shortage within a facility, it’s a poor decision not to have the labor.

Cary Grace: And Tobey, the last part that I would add that I know we’ve talked about, particularly over the past 12 months to 18 months is when you look at really kind of the fragile state of the workforce, so we do a biannual survey of nurses. And we’ll publish it in May. I just got some of the data over the past 24 hours. And if you look at the macro level satisfaction levels, for nursing career current nursing job, we saw it drop down to 71%, that number has been between 80% and 85% for a decade. And so when you look at still very high turnover rate satisfaction levels going down, there is this balance of — for a lot of our clients how do they find the balance between the cost containment. But also making sure that from a pace standpoint that they have an environment that is going to be able to retain and keep their precious staff.

Tobey Sommer: Thank you.

Operator: One moment for our next question and that will come from the line of Tim Mulrooney with William Blair. Your line is open.

Tim Mulrooney: Cary, Jeff, Kelly Landry, good afternoon.

Cary Grace: Good afternoon.

Tim Mulrooney: So there’s a lot of moving parts here with first quarter expected to be stronger, second quarter is expected to be lower than normal. So I just want to ask it in a different way. Last quarter, you laid out a framework for 2023 of more than $4 billion in annualized revenue and 15% EBITDA margins. Is that still your expectation today?

Jeff Knudson: Yes, Tim. So you’re right. The first quarter guidance is higher than what we had thought. And again, that’s primarily driven from higher bill rates, and that’s what’s also driving our expectation for a lower Q2 and that higher than normal sequential decline, we talked about earlier. But given everything that, Landry just talked about with demand increasing in the second half, and we also believe that bill rates off of that Q2 level will follow a normal seasonal pattern into Q2, that if that normal seasonality plays out in the second half, we would see a path to that full year expectation that we laid out in the last call.

Tim Mulrooney: Okay. Thanks. The last few years, you’re €“ just building on that. You’ve provided an expectation where you think bill rates ultimately settle as you exit the year. What is your expectation for bill rates as you had to exit in ‘2023?

Jeff Knudson: They really haven’t. Because they were higher in the fourth quarter and the first quarter when we thought and then with that high single-digit decline into the second quarter, they’re still exiting the year with where we originally thought they would be. It’s just they weren’t there in the fourth quarter and the first quarter.

Tim Mulrooney: Okay. Thank you.

Operator: Thank you. One moment for our next question, and that will come from the line of Mark Marcon with Robert W. Baird. Your line is open.

Mark Marcon: Hey, good afternoon, everyone. With regards to just the fourth quarter, just the rearview mirror. You mentioned some credit adjustments with regards to Nurse and Allied in the operating margin for the fourth quarter. Jeff, what was that exactly, what happened?

Jeff Knudson: Yes. So there was just a reserve for credit losses or bad debt, Mark. There was one specific MSP accounts that we have concerned out. And then also just given the macro environment, we also took a slightly larger-than-normal general reserve for expected credit losses, and that impacted Nurse and Allied, primarily is what drove those dollars.

Mark Marcon: And that MSP account is a €“ one large one? Or is it relatively well contained?

Jeff Knudson: It’s relatively well contained. It’s not one of our larger accounts.

Mark Marcon: Okay. Great. And then really appreciate the forward look into Q2. That’s extremely helpful. Cary, Jeff, kudos to you for both disclosing what you’re seeing now as it relates to that. I mean, it does sound like a lot of that is basically the change in terms of the bill rates, and it sounds like basically in Q4 and Q1, the bill rates are higher due to certain specialties that are being utilized to a greater extent. What specialties are you seeing that, that our high bill rate specialties that were a little bit higher than expected in terms of utilization in Q4 and Q1? And why would that drop off more than usual going into Q2?

Jeff Knudson: Yes. So Mark, going into the fourth quarter, our expectation for bill rates is that they would decline in the mid-single digits. They ended up coming down 2% over Q3 levels. And then really, the higher bill rate specialties is a driver of why they increase sequentially into the first quarter and that’s really just about a number of urgent needs orders that we received that carried a higher bill rate that from a mix standpoint, drove bill rates up in the first quarter and then those will predominantly roll off by the end of the first quarter as we exit into Q2.

Mark Marcon: Great. And then if I could just cheat and just ask one more. How much variance are you seeing in terms of the behavior among your 30 largest clients in terms of how they’re treating the need for cost discipline versus managing the workload on the floors?

Kelly Rakowski: Mark, it’s Kelly. I’m chuckling a little bit, because we had a lot of variation just in the makeup of those 30 across the country, different sizes, different settings, different communities that they serve. So on the one hand, it’s difficult to sort of peg consistency. But I will say from a €“ in general, Landry talked about it. We’re coming off a peak, so very high volume. There’s still the sensitivity around the financials, while I think the industry, particularly the hospital industry started to see improvement in their bottom line coming out of December, there’s still considerable financial strain on the systems, and they’re looking to their largest line item of expenses to be able to manage that going forward.

So, I would say there’s still that sensitivity to cost management, largely doing that through bill rates, through some of the urgent needs that Jeff just referred to. We’re seeing them turn to us to help them with predictive planning, utilizing our permanent resources to help them backfill so that they can bring back down those vacancy rates to more normal levels. So, high sensitivity the cost. At the same time, still a need around fulfillment. Landry mentioned there’s €“ they still need the nurses and their allied professionals on the floor, there’s challenges around retention. We hear most CHRO’s talk about, I don’t have a recruitment challenge, I have a retention challenge, I need to keep the people I have. And we know the biggest factor to retention is creating a safe positive work environment.

So they’re not €“ they don’t want to relinquish the use of contingent staff. So our teams just continue to work with them on all fronts, helping them from a short-term perspective, manage those costs, but also bringing to bear other capabilities and parts of our solution to help them with the long term. So I think that’s probably a very broad-brush universal kind of lay of the land mark.

Mark Marcon: Appreciate that, Kelly. Thank you.

Operator: Thank you. One moment for our next question, and that will come from the line of Jeff Silber with BMO Capital Markets. Your line is open.

Unidentified Analyst: Hey. This is Ryan on for Jeff. I just wanted to ask a quick question on the tech and workforce. I’m just curious, what the drivers are for the segment for the year as you lap some challenging comps and some headwinds in VMS? And do you think the language service business can continue its strong trajectory and really drive the segment going forward? Thank you.

Jeff Knudson: Yes. Thanks, Ryan. I would say when you look at the year-over-year comparisons for the rest of the year that we would still expect language services to be growing in that high-teens rate as we move through the rest of the year. As you noted, VMS will have some very tough compares, particularly in the Q2 €“ beyond Q1 and the Q2 and Q3 time frame. And they’ll also be challenged sequentially in the second quarter as some of these bill rate dynamics that we talked about on Nurse and Allied play out in the front half of the year.

Kelly Rakowski: And I’ll just add, Ryan, on Language Services, I mean, you heard Cary mentioned, we celebrated the three-year anniversary with AMN this week. That team just continues to deliver very high-quality services, very strong retention of clients as well as kind of in account growth. So we still see organic growth patterns for that business within their existing account base as they increased adoption of the model, in some cases, where we have accounts, where we might be working with health systems on a few other hospitals. They see our results and they continue to expand. And we have a strong pipeline and new acquisition there and still an opportunity to grow within our MSP base. So, just a shout out to that team for their tremendous value that they bring to their customers, and we’re just thrilled to have them as part of AMN.

Unidentified Analyst: Sure. Thank you. And just as my follow-up, given some of the clinicians rolling off in the second quarter and CFO grumblings about cost. Just wondering if there’s any room to move rates lower, offer any concessions to kind of ease the financial burden on providers for later in the year. And then are you expecting normal seasonality to return in the second half?

Jeff Knudson: The bill rate is a tricky one, because we saw bill rates go down on our orders, not necessarily on our placements throughout. Well, the bill rates in the placements did go down, but the orders went down to a level last year that it was negatively impacting bill rates because of a low pace. So that’s why we’ve got some confidence in where we think that the bill rates are going to normalize. So that’s a little bit tricky one. I think the better thing is to go and offer more solutions to help with the overall labor problem. So whether that’s offering some RPO solutions or more local type of solutions that €“ it’s not new, not something brand new, but clients are looking to try all sorts of new things right now. And then I think your other part of your question had to do with the second half of the year seasonality.

Landry Seedig: On the seasonality, we are expecting the second half of the year to play out, which would mean Q3 would typically be up modestly over Q2 and then a little bit of stronger growth in the fourth quarter over Q3 levels.

Unidentified Analyst: Got it. Thank you.

Operator: Thank you. One moment for our next question, and that will come from the line of Brian Taji Phillips with Jefferies. Your line is open.

Brian Tanquilut: Hey, good afternoon, guys. It’s Brian Tanquilut. I guess my question for the team. There’s a lot of chatter around the competitive dynamics in the space, where some of your competitors are talking about expectations for a good bit of incremental decline in bill rates going forward or their predictions. So just curious what you’re seeing in the market in terms of the competition and what you’re hearing in terms of — is there a potential for price aggressiveness from some of the players in the market at this point?

Landry Seedig: So this is Landry, Brian. Jeff mentioned that we are anticipating that sequential decline in bill rate from Q1 to Q2. From what we’re seeing from the competition, there is some pockets of small competitors out there that might make margin move or a bill rate move. It’s not something that we’ve seen as of right now from any of our large competitors.

Brian Tanquilut: Got it. Okay. Awesome. Thank you. That’s all I have.

Operator: Thank you. And speakers, I’m showing no further questions in the queue at this time. I would now like to turn the call back over to management for any closing remarks.

Cary Grace: Thank you. Before we say, our final goodbye, I know we’ve talked quite a bit about a couple of our businesses. We didn’t talk as much about PLS. So I just want to give them a big recognition for — as you go and look at throughout 2022. They had just a terrific year, including in the locums business, four consecutive quarters of hitting over $100 million of revenue. And so deserves a special shout out. Thank you all for being with us. We appreciate all the questions and all the interest. I’m going to end with how I started, which is I could not be more thrilled to be part of this wonderful AMN team, and I am looking forward to spending time with all of you in the coming weeks and months.

Operator: Thank you all for participating. This concludes today’s program. You may now disconnect.

Follow Ameron International Corp (NYSE:AMN)